Analysis shows similar outcomes for outpatient and inpatient administration of ciltacabtagene, indicating reduced resource use in outpatient settings.
OP administration of cilta-cel yielded similar effectiveness and safety outcomes relative to IP administration, while significantly reducing IP resource use. These findings support the feasibility of OP administration of cilta-cel in treating RRMM patients and its potential to reduce the burden on the healthcare system.
No takes yet. Share an insight, caveat, or question.
Janakiram et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: